- Home
- MNMD
as of 01-07-2026 3:58pm EST
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.3B | IPO Year: | N/A |
| Target Price: | $30.33 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.70 - $14.81 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered MNMD Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Mind Medicine (MindMed) Inc. (MNMD)
Chief Legal Officer
Avg Cost/Share
$13.15
Shares
11,276
Total Value
$148,244.44
Owned After
282,576
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$13.15
Shares
25,791
Total Value
$339,071.70
Owned After
778,477
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$13.15
Shares
5,600
Total Value
$73,622.64
Owned After
425,025
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Sullivan Mark | MNMD | Chief Legal Officer | Dec 26, 2025 | Sell | $13.15 | 11,276 | $148,244.44 | 282,576 | |
| Barrow Robert | MNMD | Chief Executive Officer | Dec 26, 2025 | Sell | $13.15 | 25,791 | $339,071.70 | 778,477 | |
| Karlin Dan | MNMD | Chief Medical Officer | Dec 26, 2025 | Sell | $13.15 | 5,600 | $73,622.64 | 425,025 |
Compare MNMD vs Leading Stocks
See how MNMD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MNMD Mind Medicine (MindMed) Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.